• Participant meets 2014 IWG-2 criteria for hippocampal amnestic syndrome, typical of AD, with progressive episodic memory impairment confirmed by neuropsychology. Cerebrospinal fluid markers (Aβ40, Aβ42, T-tau, p-tau) consistent with AD, or AV-45 PET imaging showing significant cortical tracer retention, in line with AD pathophysiology.

• Age range: 55-80 years.

• No visual or hearing impairment.

• Right-handed.

• Han nationality.

• Signed informed consent.

• Reliable caregivers as information providers.

• MMSE score: 10-27; CDR: 0.5-2 points.

• If receiving approved AD treatment (e.g., acetylcholinesterase inhibitor or memantine), dose must be stable for ≥3 months prior to screening and unchanged unless medically necessary.